(Alliance News) - Angle PLC on Monday announced the launch of its new Portrait Flex circulating tumour cell assay, which it said will provide valuable trial data and help advance "personalised cancer care." Read More
Angle PLC - Guildford, England-based liquid biopsy company - Hires Brett Swansiger as chief commercial officer and Karen Miller as chief scientific officer. Says Swansiger has over 20 years of experience within the molecular diagnostic and pharmaceutical industries. Most recently, he was COO at DxTerity Diagnostics, a biotechnology company based in the US. Says Miller brings a strong network of relationships within the pharmaceutical and companion diagnostic industries, having over 30 years of experience. She was most recently the CSO at Ixaka, a cell & gene therapy company. Start dates for both roles are undisclosed. Read More
Angle PLC - Guildford, England-based liquid biopsy company - Announces new contract with clinical-stage biotechnology company Artios Pharma for use of two DNA damage response assays in a Phase 1 clinical trial. Artios was Angle's first bespoke assay development customer, selecting it to develop immunofluorescence assays to detect biomarkers on tumour cells. The Phase 1 trial will begin "shortly" with completion expected around the end of 2024. Angle says the assays could later be used in larger and later-stage clinical trials. Read More
Angle PLC - Guildford, England-based liquid biopsy company - Chair Garth Selvey plans to retire from the board after interim results are released in September. Selvey has been chair since 2007. he will hand over the position of chair with immediate effect to Jan Groen, who is currently an independent non-executive director. Groen is also currently the chief executive officer and chair of Intravacc BV. Read More
(Alliance News) - Angle PLC on Friday said it had a "breakthrough" year, despite reporting an annual widened loss. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Stock prices in London closed higher, buoyed by optimism from strong retail updates, and shaking off hawkishness from the US Federal Reserve. Read More
(Alliance News) - Angle PLC on Thursday reported that it expects "growth" in 2023, albeit significantly lower than market estimates, as it anticipates its operating loss to widen. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
Angle PLC - Surrey, England-based medical diagnostics company - Says proof of concept study shows that both circulating tumour cells and cell-free circulating tumour DNA can be analysed from a single blood sample. "The results show that removal of plasma from blood samples for circulating tumour DNA analysis does not impact on the number or quality of circulating tumour cells which can be successfully isolated from the same sample using the Parsortix system," it explains. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - Angle PLC on Monday noted the publication of results from a clinical study undertaken with Wilmot Cancer Institute, at the University of Rochester, in New York. Read More